Hepatitis C eradication and improvement of cryoglobulinemia-associated rash and membranoproliferative glomerulonephritis with interferon and ribavirin after kidney transplantation

Marilyn Zeman MD1, Patricia Campbell MBChB2, Vincent G Bain MD1

Postrenal transplant hepatitis C is increasing in frequency due to the high prevalence of hepatitis C among patients with renal failure. Despite this, there is still no standard hepatitis C treatment available for renal transplanted recipients. Combination antiviral hepatitis C therapy, the standard of care in the nontransplant population, is generally avoided because of documented renal graft rejection secondary to interferon treatment. A case of a male patient with postrenal transplant hepatitis C, which was associated with cryoglobulinemia and glomerulonephritis of the graft, is presented. He was treated with standard interferon with ribavirin. Sustained viral clearance was achieved despite ongoing evidence of cryoglobulinemia. Renal function, which had been deteriorating before treatment, improved as evidenced by the stabilization of serum creatinine and marked improvement of proteinuria. In conclusion, in selected patients, combination antiviral therapy may still be a viable option postrenal transplant.

Key Words: Cryoglobulin; Hepatitis C; Interferon; Kidney transplant

Liver disease due to hepatitis C virus (HCV) postrenal transplant is a significant problem given the high incidence of HCV in patients with kidney diseases (1). Furthermore, immunosuppression can have an adverse effect on the progression of HCV. HCV can also affect the renal graft due to the development of glomerulonephritis. The treatment of chronic HCV liver or kidney disease includes combination antiviral therapy with pegylated interferon-alpha (PEGIFN-α) and ribavirin (2,3). However IFN-α (both standard and PEG) treatment has generally been avoided in the renal transplant population because of the frequent occurrence of acute graft failure secondary to rejection (4). Ribavirin alone lowers HCV RNA levels but cannot clear the virus (5). In nontransplant studies, the addition of ribavirin to PEGIFN-α has increased the rate of sustained viral response (SVR), defined as the absence of HCV RNA in serum at the end of treatment and the rate of sustained viral response (SVR), defined as the absence of HCV RNA in serum at the end of treatment and six months later, from 29% (PEGIFN-α alone) to 56% (PEGIFN-α and ribavirin) (3). In renal insufficiency, ribavirin is contraindicated due to reduced clearance of the drug and the risk of severe hemolytic anemia. However, newer evidence does support its use in moderate to severe renal disease with diligent therapeutic drug monitoring, careful ribavirin dosing and erythropoietin use (6,7).

We describe a case of postrenal transplant chronic HCV glomerulopathy associated with cryoglobulinemia treated with combination IFN-α and ribavirin therapy with resulting improvement in renal dysfunction, lack of transplant rejection and clearance of HCV.

CASE PRESENTATION

A 44-year-old man with end-stage renal disease secondary to membranoproliferative glomerulonephritis (MPGN) associated with cryoglobulinemia presented in September 1998 after testing positive for HCV, genotype 2b. He had been on peritoneal dialysis for 18 months and was being considered for renal transplant. His HCV was thought to be secondary to intravenous drug use between 1975 and 1978, and his only symptoms were those of cryoglobulinemia. These included a recurrent,
Zeman et al

raised pruritic rash on the lower extremities and mild arthralgia. Past medical history showed primary hypertension for 10 years. His medications included diltiazem sustained release 90 mg taken orally twice a day; tenazosin 10 mg taken orally daily; prazosin, one tablet taken orally twice a day; prednison 10 mg taken orally twice a day (for treatment of his vasculitis rash on the lower extremities); furosemide 40 mg taken orally daily; calcium carbonate 1000 mg taken orally daily; ranitidine 150 mg taken orally daily; epoetin alfa (Eprex, Janssen-Ortho, Canada) 50 IU/kg to 100 IU/kg taken subcutaneously twice a day; and a daily multivitamin.

On physical examination, his blood pressure was unusually high at 210/105 mmHg with no evidence of cardiac, cerebral or retinal sequelae. His abdomen was soft and nontender with no evidence of hepatomegaly or splenomegaly. Peripheral examination revealed bilateral stasis dermatitis in the lower extremities secondary to recurrent purpuric vasculitis. A skin biopsy performed the year before presentation had shown leukocytoclastic vasculitis, which was immunoglobulin- and complement-negative.

Laboratory results showed a normal complete blood count with a hemoglobin of 133 g/L (normal values 135 g/L to 175 g/L). Renal function revealed an elevated creatinine at 584 μmol/L (normal values 45 μmol/L to 125 μmol/L) with a blood urea nitrogen of 24.9 mmol/L (normal values 2.5 mmol/L to 8.0 mmol/L). Calcium was normal at 2.52 mmol/L (normal values 2.10 mmol/L to 2.60 mmol/L) with an elevated phosphorous level at 1.93 mmol/L (normal values 0.80 mmol/L to 1.45 mmol/L) and a normal alkaline phosphatase level of 91 U/L (normal values 30 U/L to 130 U/L). Liver enzymes and function tests included an alanine transferase (ALT) level of 28 U/L (normal values less than 50 U/L), albumin 28 g/L (normal values 35 g/L to 50 g/L), total bilirubin 8 μmol/L (normal values less than 20 μmol/L) and an international normalized ratio of 1.0 (normal values 0.8 to 1.2). Fasting lipid profile showed evidence of a mild increase in both cholesterol at 6.59 mmol/L and triglycerides at 6.96 mmol/L. Urinalysis revealed 3+ proteinuria, 1+ hemoglobin and cytodiagnostic evidence of coarse granular casts. A kidney biopsy performed at that time showed pauci-immune MPGN related to a type II cryoglobulinemia. The patient was HIV, antinuclear antibody and rheumatoid factor-negative. Protein serum electrophoresis was normal. C3 levels were borderline low at 0.77 g/L (normal values 0.80 g/L to 2.0 g/L) and C4 levels were normal at 0.25 g/L (normal values 0.18 g/L to 0.36 g/L).

The decision was made to attempt HCV clearance before renal transplantation and standard IFN-α 3 μU administered subcutaneously three times a week was initiated. This was subsequently decreased to 1.5 mU three times a week within two months because the patient developed anxiety, shakiness and blurry vision. The patient was eventually able to tolerate 2 mU three times a week. Ribavirin was never started because of renal failure. At the end of 12 months of IFN-α treatment, the patient was HCV RNA-negative and all his vasculitic lesions had completely disappeared, despite still being serum cryoglobulin-positive. During this time, his medications remained the same except that prazosin had been discontinued and fosinopril (Monopril, Bristol-Myers Squibb, Canada) 20 mg taken orally twice a day had been started. Prednison had been decreased from 10 mg orally twice a day to 5 mg orally daily. Four months later, he was again found to be HCV RNA-positive with a HCV 2b RNA level greater than 8.5×10⁸ IU/L (no further dilutions were performed in view of favourable HCV genetic profile) with minor recurrence of the vasculitic rash. By that time, peritoneal dialysis had failed secondary to peritonitis and hemodialysis had been initiated and the patient remained consistently adamant that he wanted to undergo renal transplantation despite risk of recurrent disease.

The patient underwent renal transplantation, receiving a kidney from an HCV genotype 2b-positive cadaveric donor. Immunosuppression consisted of tacrolimus targeted to a serum level of 12 μg/L to 15 μg/L immediately post-transplant, which was tapered down to 5 μg/L to 7 μg/L; mycophenolate mofetil (Cellcept, Hoffmann-La Roche Ltd, Canada) 1 g taken twice a day; and prednison. The prednison has never been fully tapered off and remains at least at 6.5 mg taken orally daily so that he could remain rash free. Baseline creatinine was 97 μmol/L (normal values 45 μmol/L to 125 μmol/L) by one year post-transplant. Urine protein to creatinine ratio and ALT levels remained normal. Treatment of his recurrent HCV (HCV 2b RNA level greater than 8.5×10⁸ IU/L) was initially withheld because liver function remained unaffected and IFN-α would increase his risk of rejection. Over the course of the next year, renal function deteriorated despite adequate immunosuppression and avoidance of additional nephrotoxic agents. A renal allograft biopsy performed 20 months post-transplant showed no evidence of graft rejection; however, there was noted absence of immunoglobulin G consistent with MPGN from HCV. Furthermore, the pathology was noted to be similar to that seen pretransplant, which is also consistent with HCV recurrence or persistence. C4 and C3 levels were 0.05 g/L (normal values 0.18 g/L to 0.36 g/L) and 1.00 (normal values 0.80 g/L to 2.00 g/L), respectively. Both triglyceride and albumin levels remained normal. By 23 months post-transplant, creatinine had increased to 126 μmol/L (normal values 45 μmol/L to 125 μmol/L) and urinalysis showed 3+ proteinuria. Protein to creatinine ratio had increased to 428 mg/mmol (normal values less than 13 mg/mmol) (calculated protein excretion 5.7 g/day at 24 months post-transplant). The urine to creatinine ratio is known to accurately and reliably estimate the level of proteinuria, as measured by 24 h urine protein excretion (0.93 by linear regression), with high sensitivity (97% to 99%) and specificity (95% to 99%) (8).

Because of his deteriorating renal function and proteinuria, HCV antiviral combination therapy with ribavirin and IFN-α 2b was restarted 23 months post-transplant at doses of 3 μU taken subcutaneously three times a week and 200 mg taken orally twice a week, respectively, for a total course of 24 weeks. Despite ongoing hemolytic anemia requiring blood transfusions every one to two weeks and an increase in his darbepoetin alfa (Aranesp, Amgen Canada Inc) dose, the patient’s overall condition improved; Blood pressure stabilized to approximately 130/70 mmHg, ALT remained normal and the vasculitic rash completely disappeared. By the end of 24 weeks of combination treatment, HCV RNA remained undetectable (detection limit of assay 600 HCV IU/mL) and continued to be undetectable 24 weeks after treatment.

With IFN and ribavirin treatment, the patient’s renal function also stabilized (Figure 1). Before this treatment period (within the same month), 8 mg daily of candesartan (Atacand, AstraZeneca Canada Inc) was taken orally which was adjusted up to 16 mg daily taken orally. Over the 24 week combination treatment course, his creatinine level remained stable, ranging from 126 μmol/L at the beginning of treatment to 133.25 μmol/L.
HCV-associated renal disease can occur in both native and transplanted kidneys. These diseases commonly include membranous nephropathy and MPGN with or without mixed cryoglobulinemia. In the HCV renal transplant population, recurrent MPGN glomerulopathy presents as proteinuria and renal graft failure (9). The patient described here was diagnosed with HCV following his diagnosis of MPGN with mixed cryoglobulinemia in his native kidneys. HCV load decreased with treatment, as did his symptoms of cryoglobulinemia, suggesting that HCV was the cause of his renal dysfunction. After renal transplantation, despite temporary improvements in creatinine plasma levels, proteinuria persisted and allograft biopsy was consistent with recurrence of his MPGN. HCV kidney disease is more commonly seen in transplant (both renal or hepatic) recipients than in the native kidneys of HCV-positive individuals (9,10). This thought to be a result of higher HCV RNA levels secondary to the immunosuppression, which in turn leads to increased viral complex deposition in the glomerulus (11). Being HCV-positive is considered to be an independent risk factor for reduced renal allograft survival and patient death (12).

Renal transplant is still the best therapy for end-stage renal disease patients on renal replacement therapy who are known to be HCV-positive (12). The prevention of HCV-associated glomerulonephritis with pretransplant virus elimination remains the standard of therapy but results are suboptimal, especially in genotype 1, because only PEGIFN-α monotherapy can be used. Current results suggest that in these individuals, SVR can only be obtained in 13% to 21% (3). In nonresponders or in those who relapse after cessation of therapy, there is often disease recurrence after cessation of therapy or post-transplant. In the transplant population, data for IFN-α use are limited. Reports indicate induction of steroid-resistant renal allograft rejection when initially used for prevention of cytomegalovirus infection shortly after renal transplantation (13). In this small placebo-controlled trial, six of 21 patients receiving low-dose recombinant IFN-α 2C compared with zero of 19 patients receiving placebo, in addition to their cyclosporine and methylprednisolone immunosuppression, suffered irreversible transplant rejection (13). To date, there is no literature with respect to PEGIFN-α treatment and renal transplant rejection. Acute renal allograft rejection is well-documented in individuals with HCV, treated with IFN-α, with an incidence of between 15% and 73% (14). Table 1 summarizes the reported experience with IFN-α therapy in the early post-transplant period. An exceptionally high incidence of acute rejection and graft loss was seen. Chan et al (15) suggested that if IFN-α is given, it should not be given in the early transplant period, and that patients should have stable renal function when the drug is started. Ichikawa et al (16), however, described a case of acute renal allograft rejection after IFN treatment was started 17 months post-transplant.

There are two double-blind trials in which a higher incidence of renal allograft dysfunction was not seen after initiation of IFN treatment (17,18). These studies used lower doses of IFN as cytomegalovirus prophylaxis in renal transplant recipients. With the available literature, it would appear that the risk of renal allograft rejection is increased and a risk benefit decision has to be made individually, taking into account the risk of renal allograft rejection and the risk of HCV-related renal disease recurrence. This decision will depend on the individual patient’s risk factors for renal allograft dysfunction and HCV-related renal disease recurrence, as well as the patient’s overall health status and preferences.
account the likelihood of response (HCV genotype versus the patients individual risk of rejection). One might expect similar results with PEGIFN as with IFN; however, there has only been one study to date looking for renal allograft rejection after PEGIFN treatment. As shown in Table 1, the present study switched three patients from IFN to PEGIFN during treatment and none of those three developed renal allograft rejection (19).

It is possible that with today’s more potent immunosuppressive agents that the risk of rejection and graft loss may be less. Interestingly, despite the patients normalization of kidney function and sustained clearance of HCV, his cryoglobulinemia, as determined by qualitative cryoglobulin electrophoresis, with associated vasculitic lesions persists. Notwithstanding a well-documented association between HCV and cryoglobulinemia (20), there are reports of HCV clearance and ongoing cryoglobulinemia. Similar to our patient, Yamabe et al (21) presented a case of HCV clearance with documented SVR, improvement of MPGN on renal biopsy and continuation of cryoglobulinemia after a two-month intense course of standard IFN-α treatment (10 mU subcutaneously daily for two weeks followed by 2 mU three times daily for six weeks ) in a 42-year-old man. Sarac et al (22) suggested that a higher dosage and longer course of IFN treatment (3 mU taken subcutaneously twice a week, increased to 10 mU taken subcutaneously twice a week for six weeks, for a total duration of treatment of 7.5 months) would be needed to clear the cryoglobulins, consistent with the logic that the disappearance of anti-HCV antibodies would be slower than that of HCV RNA (21). Alternatively, it has been reported that there may be persistence of HCV RNA including replicative intermediates in peripheral blood mononuclear cells using highly sensitive assays (23), and this may fuel the persistence of cryoglobulinemia.

### Summary
We present a case of deteriorating renal function and proteinuria due to recurrent MPGN in a HCV-positive renal allograft recipient who was successfully treated with a post-transplant course of standard IFN-α (10 mU sc tid) for three months followed by 2 mU sc tid for six months.

---

### Table 1
The use of interferon (IFN) for hepatitis C virus (HCV) and renal allograft rejection

<table>
<thead>
<tr>
<th>Reference</th>
<th>HCV genotype</th>
<th>n</th>
<th>IFN treatment received</th>
<th>Acute rejection</th>
<th>Cleared HCV</th>
</tr>
</thead>
<tbody>
<tr>
<td>Durlik et al, 1998 (24)</td>
<td>Unknown</td>
<td>11</td>
<td>IFN-α 3 mU sc tiw for 3 to 12 months</td>
<td>1/11</td>
<td>0/11*</td>
</tr>
<tr>
<td>Rostaing et al, 1996 (25)</td>
<td>Unknown</td>
<td>16</td>
<td>IFN-α 2b 3 mU sc tiw for 6 months or until discontinued</td>
<td>0/16</td>
<td></td>
</tr>
<tr>
<td>Kramer et al, 1984 (26)</td>
<td>Unknown</td>
<td>8</td>
<td>IFN 36 mU im tiw for 1.5 months then tiw for 1.5 months</td>
<td>8/8</td>
<td>Unknown</td>
</tr>
<tr>
<td>Tokumoto et al, 1999 (27)</td>
<td>1b (3 patients)</td>
<td>6</td>
<td>IFN-α 5-10 mU sc qd 1-14 days and then 5 to 10 mU sc tiw for 2 to 24 weeks</td>
<td>2/6</td>
<td>3/6*</td>
</tr>
<tr>
<td>Hanafusa et al, 1998 (14) (subgroup analysis)</td>
<td>1b (9 patients)</td>
<td>10</td>
<td>IFN-α 2b 9 mU qd for 2 weeks and tiw for 22 weeks</td>
<td>4/10</td>
<td>1/10*</td>
</tr>
<tr>
<td>Hanafusa et al, 1998 (14) (subgroup analysis)</td>
<td>2a (2 patients)</td>
<td>2b (1 patient)</td>
<td>2/10</td>
<td>1/10*</td>
<td></td>
</tr>
<tr>
<td>Chan et al, 1993 (15)</td>
<td>Unknown</td>
<td>1</td>
<td>IFN-α 1.5 mU sc tiw tapered to maximum 5 mU tiw and tapered off over 9 months</td>
<td>1/1</td>
<td>1/1*</td>
</tr>
<tr>
<td>Ozgur et al, 1995 (28)</td>
<td>Unknown</td>
<td>5</td>
<td>IFN-α 4.5 mU sc tiw until discontinued (2 to 6 months)</td>
<td>2/5</td>
<td>No in 3/5</td>
</tr>
<tr>
<td>Takahara et al, 1995 (29)</td>
<td>Unknown</td>
<td>2</td>
<td>IFN-α 6 mU six times a week for 3 weeks and then tiw for 2 months (1 patient) IFN-α 6 mU qd for 6 months (1 patient)</td>
<td>1/2</td>
<td>Unknown</td>
</tr>
<tr>
<td>Konishi et al, 2004 (30)</td>
<td>2b</td>
<td>1</td>
<td>IFN-β 6 mU iv qd for 1 month</td>
<td>0/1</td>
<td>1/1*</td>
</tr>
<tr>
<td>Therret et al, 1994 (31)</td>
<td>Unknown</td>
<td>9</td>
<td>IFN-α 3 mU tiw sc for 6 months</td>
<td>0-1/9 (the one patient may have been both HCV and HBV)</td>
<td>Unknown</td>
</tr>
<tr>
<td>Tang et al, 2003 (32)</td>
<td>1a (1 patient)</td>
<td>1b (1 patient)</td>
<td>2 (1 patient)</td>
<td>6a (1 patient)</td>
<td></td>
</tr>
<tr>
<td>Magnone et al, 1994 (33)</td>
<td>Unknown</td>
<td>6</td>
<td>IFN-α 2 to 5 mU sc tiw for 0.3 to 13 months</td>
<td>5/7</td>
<td>Unknown</td>
</tr>
<tr>
<td>Luciani et al, 2003 (34)</td>
<td>1b (after transplant)</td>
<td>1</td>
<td>IFN-α 6 mU qd for 18 days, then 6 mU tiw for total of 6 months</td>
<td>0/1</td>
<td>1/1*</td>
</tr>
<tr>
<td>Baid et al, 2003 (19)</td>
<td>Unknown in 10 patients. In 2 who rejected 1a (1 patient) and 2a/2c (1 patient)</td>
<td>12</td>
<td>IFN 1.5 mU sc tiw and increased to 3 mU sc tiw in 3 patients. IFN changed to PEGIFN 1 µg/kg to 1.5 µg/kg sc weekly. Total treatment 3 to 89 months</td>
<td>2/12</td>
<td>4/12*</td>
</tr>
</tbody>
</table>

Patients documented as being hepatitis B virus (HBV) positive in addition to HCV positive are not included. Patients who received a combined liver and renal transplant are not included. *HCV clearance as documented by undetectable HCV viral load; †six of 16 patients in Rostaing et al (25) were documented as having acute renal failure that could not be classified as acute rejection by the Banff criteria; nine of 16 patients also discontinued IFN-α due to side effects; ‡HCV clearance as documented by liver biopsy and/or biochemical response. im Intramuscular; iv Intravenously; PEG Pegylated; qd Daily; sc Subcutaneously; tiw Three times a week
of IFN-α and ribavirin combination therapy. Despite HCV clearance, which has been sustained for over two years, symptomatic cryoglobulinemia continues. This case illustrates that carefully selected patients with HCV postrenal transplant can be considered for treatment, provided adequate immunosuppression is maintained and they are carefully monitored. Furthermore, cryoglobulinemia-related complications may be reduced, but not completely eliminated, with viral clearance.

REFERENCES
